- Home
- BRNS vs GANX Comparison
BRNS vs GANX Comparison
Compare BRNS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- GANX
- Stock Information
- Founded
- BRNS 2016
- GANX 2017
- Country
- BRNS United Kingdom
- GANX United States
- Employees
- BRNS N/A
- GANX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- GANX Health Care
- Exchange
- BRNS Nasdaq
- GANX Nasdaq
- Market Cap
- BRNS 52.0M
- GANX 41.9M
- IPO Year
- BRNS 2021
- GANX 2021
- Fundamental
- Price
- BRNS $0.97
- GANX $1.85
- Analyst Decision
- BRNS Strong Buy
- GANX Strong Buy
- Analyst Count
- BRNS 2
- GANX 4
- Target Price
- BRNS $4.00
- GANX $7.75
- AVG Volume (30 Days)
- BRNS 31.7K
- GANX 281.8K
- Earning Date
- BRNS 11-06-2024
- GANX 11-14-2024
- Dividend Yield
- BRNS N/A
- GANX N/A
- EPS Growth
- BRNS N/A
- GANX N/A
- EPS
- BRNS N/A
- GANX N/A
- Revenue
- BRNS $14,969,000.00
- GANX N/A
- Revenue This Year
- BRNS N/A
- GANX N/A
- Revenue Next Year
- BRNS N/A
- GANX $300.03
- P/E Ratio
- BRNS N/A
- GANX N/A
- Revenue Growth
- BRNS 106.21
- GANX N/A
- 52 Week Low
- BRNS $0.88
- GANX $0.89
- 52 Week High
- BRNS $4.16
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- BRNS 30.37
- GANX 39.86
- Support Level
- BRNS $1.28
- GANX $1.64
- Resistance Level
- BRNS $1.52
- GANX $2.34
- Average True Range (ATR)
- BRNS 0.13
- GANX 0.27
- MACD
- BRNS -0.04
- GANX -0.09
- Stochastic Oscillator
- BRNS 14.09
- GANX 19.90
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.